BACKGROUND: Sentinel lymph node (SLN) biopsy in patients undergoing prophylactic mastectomy (PM) remains controversial. We sought to determine the incidence of finding occult cancer and the frequency of SLN positivity in patients undergoing contralateral PM. METHODS: Medical records of patients undergoing bilateral mastectomy at our institution from 2003 to 2008 were reviewed (n = 115). Eight patients (6.9%) had known bilateral cancer; an additional eight patients (6.9%) underwent BPM for risk reduction. The remaining 99 patients who had ipsilateral breast cancer and underwent contralateral PM formed the cohort of interest for this study. Univariate and multivariate analyses to determine factors correlating with occult malignancy and SLN positivity in the PM specimen were performed using SPSS ver. 17 (SPSS Inc., Chicago, IL). RESULTS: The median patient age was 50 y, and median ipsilateral tumor size was 1.7 cm. Occult contralateral malignancy was found in eight (8.1%); of these, six (75.0%) had DCIS only. A positive SLN was found on the prophylactic side in 2 (2.0%) patients. Both had ipsilateral inflammatory cancer, and over 15 positive ipsilateral lymph nodes post-neoadjuvant chemotherapy. Ipsilateral inflammatory breast cancer was correlated with the finding of invasive cancer in the contralateral PM (P = 0.006), and both the finding of ipsilateral inflammatory breast cancer and number of positive lymph nodes correlated with the finding of a positive contralateral SLN. CONCLUSION: The incidence of occult malignancy in PM is low (2%). However, patients with ipsilateral inflammatory cancer are at high risk of contralateral malignancy; SLN biopsy on the prophylactic side in these patients may be warranted.
BACKGROUND: Sentinel lymph node (SLN) biopsy in patients undergoing prophylactic mastectomy (PM) remains controversial. We sought to determine the incidence of finding occult cancer and the frequency of SLN positivity in patients undergoing contralateral PM. METHODS: Medical records of patients undergoing bilateral mastectomy at our institution from 2003 to 2008 were reviewed (n = 115). Eight patients (6.9%) had known bilateral cancer; an additional eight patients (6.9%) underwent BPM for risk reduction. The remaining 99 patients who had ipsilateral breast cancer and underwent contralateral PM formed the cohort of interest for this study. Univariate and multivariate analyses to determine factors correlating with occult malignancy and SLN positivity in the PM specimen were performed using SPSS ver. 17 (SPSS Inc., Chicago, IL). RESULTS: The median patient age was 50 y, and median ipsilateral tumor size was 1.7 cm. Occult contralateral malignancy was found in eight (8.1%); of these, six (75.0%) had DCIS only. A positive SLN was found on the prophylactic side in 2 (2.0%) patients. Both had ipsilateral inflammatory cancer, and over 15 positive ipsilateral lymph nodes post-neoadjuvant chemotherapy. Ipsilateral inflammatory breast cancer was correlated with the finding of invasive cancer in the contralateral PM (P = 0.006), and both the finding of ipsilateral inflammatory breast cancer and number of positive lymph nodes correlated with the finding of a positive contralateral SLN. CONCLUSION: The incidence of occult malignancy in PM is low (2%). However, patients with ipsilateral inflammatory cancer are at high risk of contralateral malignancy; SLN biopsy on the prophylactic side in these patients may be warranted.
Authors: Cynthia L Miller; Michelle C Specht; Melissa N Skolny; Lauren S Jammallo; Nora Horick; Jean O'Toole; Suzanne B Coopey; Kevin Hughes; Michele Gadd; Barbara L Smith; Alphonse G Taghian Journal: Breast Cancer Res Treat Date: 2012-09-01 Impact factor: 4.872
Authors: Sara Câmara; Daniela Pereira; Saudade André; Beatriz Mira; Fátima Vaz; Rodrigo Oom; José Carlos Marques; João Leal de Faria; Catarina Rodrigues Dos Santos Journal: Int J Breast Cancer Date: 2018-01-01
Authors: Judy C Boughey; Deanna J Attai; Steven L Chen; Hiram S Cody; Jill R Dietz; Sheldon M Feldman; Caprice C Greenberg; Rena B Kass; Jeffrey Landercasper; Valerie Lemaine; Fiona MacNeill; Julie A Margenthaler; David H Song; Alicia C Staley; Lee G Wilke; Shawna C Willey; Katharine A Yao Journal: Ann Surg Oncol Date: 2016-07-28 Impact factor: 5.344
Authors: Vivianne Freitas; Pavel Crystal; Supriya R Kulkarni; Sandeep Ghai; Karina Bukhanov; Jaime Escallon; Anabel M Scaranelo Journal: Cancer Med Date: 2016-03-18 Impact factor: 4.452